

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	8	Attorney Docket Number	024047.370B-US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2,881,173-B1	04-07-1959	Wilhelm Wenner	
	AB	US-3,624,114-B1	11-30-1971	Jean V. Morelle	
	AC	US-3,882,228-B1	05-06-1975	Boncey et al.	
	AD	US-3,887,700-B1	06-03-1975	Boncey et al.	
	AE	US-3,993,775-B1	11-23-1976	Williams	
	AF	US-4,100,160-B1	07-11-1978	Walser	
	AG	US-4,296,127-B1	10-20-1981	Walser	
	AH	US-4,309,415-B1	01-05-1982	Horrobin	
	AI	US-4,314,989-B1	02-09-1982	Rosen	
	AJ	US-4,333,484-B1	06-08-1982	Kentis	
	AK	US-4,386,072-B1	05-31-1983	Horrobin et al.	
	AL	US-4,624,919-B1	11-25-1986	Kokusho et al.	
	AM	US-4,683,298-B1	07-28-1987	Yalpani	
	AN	US-4,699,900-B1	10-13-1987	Bayol et al.	
	AO	US-4,713,373-B1	12-15-1987	Bayol et al.	
	AP	US-4,855,136-B1	08-08-1989	Horrobin et al.	
	AQ	US-4,900,724-B1	02-13-1990	Kato et al.	
	AR	US-4,925,833-B1	05-15-1990	McNamara et al.	
/S.W.	AS	US-4,994,457-B1	02-19-1991	Crawford et al.	
	AT	US-5,084,482-B1	01-28-1992	Hirsch et al.	
	AU	US-5,137,712-B1	08-11-1992	Kask et al.	
	AV	US-5,145,841-B1	09-08-1992	Cullis-Hill et al.	
	AW	US-5,215,759-B1	06-01-1993	Mausner	
	AX	US-5,225,192-B1	07-06-1993	Lovreich	
	AY	US-5,258,371-B1	11-02-1993	Golub et al.	
	AZ	US-5,262,163-B1	11-16-1993	Rancurel	
	AA1	US-5,288,503-B1	02-22-1994	Wood et al.	
	AB1	US-5,354,560-B1	10-11-1994	Lovreich	
	AC1	US-5,364,845-B1	11-15-1994	Henderson	
	AD1	US-5,354,853-B1	10-11-1994	Staveski et al.	
	AE1	US-5,411,988-B1	05-02-1995	Bockow et al.	
	AF1	US-5,422,111-B1	06-06-1995	Huc et al.	
	AG1	US-5,449,521-B1	09-12-1995	Lovreich	
	AH1	US-5,474,757-B1	12-12-1995	Yang	
	AI1	US-5,480,873-B1	01-02-1996	Brunavs et al.	
	AJ1	US-5,498,411-B1	03-12-1996	Rancurel	
	AK1	US-5,569,469-B1	10-29-1996	Lovreich	
	AL1	US-5,587,363-B1	12-24-1996	Henderson	
	AM1	US-5,589,577-B1	12-31-1996	Peltonen et al.	
	AN1	US-5,658,767-B1	08-19-1997	Kyle	
	AO1	US-5,668,172-B1	09-16-1997	Gallagher et al.	
	AP1	US-5,670,695-B1	09-23-1997	Di Napoli	
	AQ1	US-5,770,209-B1	06-23-1998	Grotendorst et al.	
	AR1	US-5,843,919-B1	12-01-1998	Burger	
	AS1	US-5,891,465-B1	04-06-1999	Keller et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449A/B/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b> Application Number <b>Continuation of 10/192,318</b> Filing Date <b>April 15, 2004</b> First Named Inventor <b>Todd R. Henderson</b> Art Unit <b>N/A</b> Examiner Name <b>Not Yet Assigned</b> Attorney Docket Number <b>024047.370B-US02</b>	
Sheet	2	of	8		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	BA	WO-WO 88/07060		09-22-1988			
	BB	GB-UK 2 223 943-A1		04-25-1990			
	BC	EP-EP 0 609 001-A2		08-03-1994			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>2</sup>
	CA	Ackerman, Lowell, "Dermatologic Uses of Fatty Acids in Dogs and Cats," Veterinary Medicine (December 1995).					
	CB	Ackerman, Lowell, "Reviewing the Biochemical Properties of Fatty Acids," Veterinary Medicine (December 1995).					
	CC	Ahrens, F., Pharmacology, Williams & Wilkins, pp. 174-75 (1996).					
	CD	Amin, A.R. et al., "A novel mechanism of action of tetracyclines: effects on nitric oxide synthases," Proc. Natl. Acad. Sci. USA 93(24): 14014-9, abstract (Nov. 26, 1996).					
	CE	Anderson, M.A. et al., "Results of a Survey of Small-Animal Practitioners on the Perceived Clinical Efficacy and Safety of an Oral Nutraceutical," Proceedings of AcVS, Orlando, abstract (in press) (Oct. 1997).					
	CF	Arduini, A., "Possible Mechanism of Inhibition of Nitrite-Induced Oxidation of Oxyhemoglobin by Ergothioneine and Uric Acid," Arch. Biochem. Biophys., 294(2): 398-403, abstract (May 1992).					
	CG	Artrodar Diacerein.					
	CH	Anuma, O.I. et al., "Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite," Biochem. Biophys. Res. Commun. 231(2): 389-91, abstract (Feb. 13, 1997).					
	CI	Asmus, K.D. et al., "One-electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C," Biochem. J. 315(Pt. 2): 625-9, abstract (1996).					
	CJ	Baldessarini, R., "Neuropharmacology of S-Adenosyl Methionine," American Journal Medicine, 83(5A): 95-103 (1987).					
	CK	Barcelo et al., "Effect of S-Adenosylmethionine on Experimental Osteoarthritis in Rabbits," The American Journal of Medicine, 83(5A): 55-59 (Nov. 20, 1987).					
	CL	Barker, J.D. et al., "Chronic Excessive Acetaminophen Use and Liver Damage," Ann. Intern. Med. 87(3): 299-301, abstract (Sept. 1977).					
	CM	Bartolucci, C., "Chondroprotective action of chondroitin sulfate," Int. J. Tiss. React., XIII (6) 311-317 (1991).					
	CN	Becconica, E., "Diacetylthein and rhein: in vivo and in vitro effect on lymphocyte membrane fluidity," Pharmacol. Res., 22 (3): 277-85 (1990) abstract.					
	CO	Beekman, B. et al., "Doxycycline inhibits collagen synthesis by bovine chondrocytes cultured in alginate," Biochem. Biophys. Res. Commun., 237(1): 107-10, abstract, (Aug. 8, 1997).					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	024047.370B-US02
Sheet	3	of	8		

CP	Beren, J. et al., "Therapeutic Effect of Cosamin on Autoimmune Type II Collagen Induced Arthritis in Rats. Proceedings of the North American Veterinary conference (Innovations and New Product Applications in Veterinary Practice), p. 35 abstract (January 1997).
CQ	Berger et al., "A New Medical Approach to the Treatment of Osteoarthritis," The American Journal of Medicine, 5A: 84-88 (Nov. 20, 1987).
CR	Blotman, F. et al., "Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis," Rev. Rheum. Engl. Ed., 64(120): 825-34.
CS	Boothe, D. et al., "Round Table Discussion of Degenerative Joint Disease in Dogs," Canine Practice, 21(1-4): 1-16 (Jan/Feb. - June/July, 1996).
CT	Borelli, F. et al., "Additional Pharmacological Aspects of Orgotein, A Metalloprotein with Superoxide-Dismutase Activity," Arzneimittelforschung, 29f: 781-785 (1979).
CU	Boumediene, K. et al., "Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta 1 and beta 2 in cultured articular chondrocytes," Arthritis Rheum., 42(1): 148-56, abstract (Jan. 1999).
CV	Brandt, K.D., "Compensation and decompensation of articular cartilage in osteoarthritis," Agents Actions, 40(3-4): 232-4, abstract (Nov. 1993).
CW	Brandt, K.D., et al., "Effects of diacerhein in an accelerated canine model of osteoarthritis," Osteoarthritis Cartilage, 5(6): 438-49, abstract (Nov. 1997).
CX	Brooks, P.M., "Clinical management of rheumatoid arthritis," The Lancet, 341: 286-290.
CY	Brummel, M.C., "In Search of a Physiological Function for L-ergothioneine," Med. Hypotheses, 18(4): 351-70 abstract (Dec. 1985).
CZ	Brummel, M.C., "In Search of a Physiological Function for L-ergothioneine,-II," Med. Hypotheses, 30(1): 39-48 (Sept. 1989).
CA1	Bucci, L., "Chondroprotective agents: Glucosamine Salts and Chondroitin Sulfates," Townsend Letter for Doctors, pp. 52-54 (Jan. 1994).
CB1	Cargoni, A. et al., "In vitro administration of ergothioneine failed to protect isolated ischaemic and reperused rabbit heart," Biochem. Biophys. Acta., 1270(2-3): 173-8, abstract (April 24, 1995).
CC1	Carney, M., "Neuropharmacology of S-Adenosyl Methionine," Clinical Neuropharmacology, 9(3): 235-243 (1986).
CD1	Champe, P., Biochemistry, 2nd Edition, J.B. Lippincott Co., Philadelphia, 1994, pp. 248, 250 and 265.
CE1	Champe, P. and Harvey, R.A., "Glycosaminoglycans", Lippincott's Illustrated Reviews: Biochemistry (2nd ed.), pp. 148-151 (1994).
CF1	Clark, D.M., DVM, "The Biochemistry of Degenerative Joint Disease and Its Treatment," Continuing Education Article 9 13(2): 275-281.
CG1	Cotran et al., Pathologic Basis of Disease, p. 423 (1994).
CH1	Cotran, R. et al., Pathologic Basis of Disease, 5th ed., Saunders, 1994, pp. 40-41.
CI1	Debord, P. et al., "Influence of renal function on the pharmacokinetics of diacerin after a single oral dose," Eur. J. Drug Metab. Pharmacokin., 19(1): 13-9, abstract (Jan-Mar. 1994).
CJ1	Degenhardt, M. et al., "Quality control of pentosan polysulfate by capillary zone electrophoresis using indirect detection," J. Chromatogr. A., 817(1-2): 297-306, abstract (Aug. 21, 1998).
CK1	Di Padova, C., "S-Adenosylmethionine in the Treatment of Osteoarthritis," The American Journal of Medicine, 83(5A): 60-65 (Nov. 20, 1987).
CL1	Dougados, Maxime, "The current Classification of Drugs in Osteoarthritis and the Recommendations for the Development," Euler '96 IX Symposium Madrid, 7-10 October 1996.
CM1	Egorov, S. Yu et al., "Quenching of singlet molecular oxygen by cosinone and related antioxidants. Monitoring 1270-nm phosphorescence in aqueous media," Biochem. Mol. Biol. Int., Ap44(4): 687-94, abstract (1997)
CN1	Ettinger, W.H. et al., "Physical Disability from Knee Osteoarthritis: The Role of Exercise as an

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Application Number		Continuation of 10/192,318			
Filing Date		April 15, 2004			
First Named Inventor		Todd R. Henderson			
Art Unit		N/A			
Examiner Name		Not Yet Assigned			
Attorney Docket Number		024047.370B-US02			

Sheet	4	of	8
-------	---	----	---

		Intervention. Medical Science Sports Exercise, abstract (Dec. 1994).	
	CO1	"Fatty Acids in Foods and Their Health Implication."	
	CP1	Fransen, M. et al., "A Revised Group Exercise Program for Osteoarthritis of the Knee," Physiother. Res. Int. 2(1): 30-41, abstract.	
	CQ1	Fry, S.W. and Seef, L.B., "Hepatotoxicity of Anesthetics and Anti-Inflammatory Agents," Gastroenterol. Clin. North Am. 24(4): 875-905, abstract (Dec. 1995).	
	CR1	Galli, C., "Dietary Omega 3 and Omega 6 Fatty Acids, Biological Effects and Nutritional Essentiality," 297-307, Plenum Press.	
	CS1	Ghosh, P. et al., "Second-Line Agents in Osteoarthritis." In: Second-Line Agents in the Treatment of Rheumatic Diseases. Marcel-Dekker, Inc., New York, pp. 353-427 (1992).	
	CT1	Girre, C. et al., "Increased Metabolism of Acetaminophen in Chronically Alcoholic patients," Alcohol Clin. Exp. Res. 17(1): 170-3, abstract (Feb. 1993).	
	CU1	Goodman, A. and Gilman, L., The Pharmacological Basis of Therapeutics, 7th ed., MacMillan Publishing Co., pp. 692-95 (1985).	
	CV1	Han, J.S., "Effects of Various Chemical Compounds on Spontaneous and Hydrogen Peroxide Induced Reversion in Strain TA104 of Salmonella typhimurium," Mutant Res., 265(2): 77-84 (1992) abstract.	
	CW1	Hanson, R.R., et al., "The Clinical Profile of a Glucosamine-Chondroitin Sulfate Compound in a Double-Blinded, Placebo-Controlled, Randomized Trial as a Selective Symptom Modifying Nutraceuical for Navicular Syndrome: Current Data and Perspectives," Veterinary Orthopedic Society, 25th Annual Conference, Snowmass, Colorado (Feb. 21-28, 1998).	
	CX1	Hanson, R.R. et al., "Evaluation of the Clinical Efficacy of a Nutraceuical in the Treatment of Navicular Syndrome: A Double-Blinded Placebo-Controlled Randomized Clinical Trial," ACVS Veterinary Symposium, ACVS Abstract No. 38, pp. 9-10 (Oct. 16-19, 1997).	
	CY1	Hanson, R.R. et al., "Oral Glycosaminoglycans in Treatment of Degenerative Joint Disease in Horses," Equine Practice, 18(10): 18-22 (Nov./Dec. 1996).	
	CZ1	Hanson, R.R. et al., "Oral Treatment with a Glucosamine-chondroitin sulfate compound for DJD in Horses: 25 cases," Equine Practice, pp. 16-22 (1997).	
	CA2	Hardie, Elizabeth M., DVM, "Slow-Acting Disease-Modifying Osteoarthritis Agents," Veterinary Clinics of North America: Small Animal Practice, 27(4): 950-952.	
	CB2	Hardingham, T.E. et al., "Proteoglycans: Many Forms and Many Functions," FASEB J., 6:861-862, abstract (1992).	
	CC2	Hartman, P.E. et al., "Direct interception of mutagens and carcinogens by biomolecules," Basic Life Sci., 61: 35-36, abstract (1993).	
	CD2	Hartman, Philip E., "Ergothioneine as Antioxidant," Methods in Enzymology, 186: 310-318, Academic Press, Inc. (1990).	
	CE2	Hebborn P. et al., "Action of topically applied arachidonic acid on the skin of patients with psoriasis," Arch. Dermatol., 124(3): 387-91, abstract (Mar. 1988).	
	CF2	Hellio, M.P. et al., "The Effects of Glucosamine Sulfate on Human Osteoarthritic Chondrocytes in Vitro Investigation," Eular '96 IX Symposium Madrid, 7-10 October 1996.	
	CG2	Henrotin, Y.E. et al., "Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes," Clin. Rheumatol. 17(1): 31-9, abstract (1998).	
	CH2	Huber, W., Orgotein-(bovine Cu-Zn superoxide dismutase), an anti-inflammatory protein drug: discovery toxicology and pharmacology," Eur. J. Rheumatol. Inflamm. 4(2): 173-82 (1981).	
	CI2	Huber, W. et al., "Superoxide Dismutase Pharmacology and Orgotein Efficacy: New Perspectives," In: Biological and Clinical Aspects of Superoxide and Superoxide Dismutase. Developments in Biochemistry (Bannister, W.H., Bannister, J.V., eds., Elsevier, New York-Amsterdam-Oxford IL: 395-407 (1980).	
	CJ2	Hulse, D., "Treatment Methods for Pain in the Osteoarthritic Patients." In: In the veterinary clinics of N. America, small animals practice clinical pharmacology and therapeutics, Vol. 28(2): 373.	

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>			<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">Continuation of 10/192,318</td> </tr> <tr> <td>Filing Date</td> <td>April 15, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Todd R. Henderson</td> </tr> <tr> <td>Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>024047.370B-US02</td> </tr> </table>		Application Number	Continuation of 10/192,318	Filing Date	April 15, 2004	First Named Inventor	Todd R. Henderson	Art Unit	N/A	Examiner Name	Not Yet Assigned	Attorney Docket Number	024047.370B-US02
Application Number	Continuation of 10/192,318															
Filing Date	April 15, 2004															
First Named Inventor	Todd R. Henderson															
Art Unit	N/A															
Examiner Name	Not Yet Assigned															
Attorney Docket Number	024047.370B-US02															
Sheet	5	of	8													

CK2	Hulse, D.S. et al., "The Effect of Cranial Cruciate Deficient and Reconstructed Stifle Joints in Dogs," Proceedings of the Veterinary Orthopedic Society, San Francisco, CA (in press) 1998).
CL2	Janicak, P.G. et al., S-Adenosylmethionine in Depression, Alabama Journal of Medical Sciences, 25(3): 306-313 (1988).
CM2	Jepsen, J.V. et al., "Long-term experience with pentosanpolysulfate in interstitial cystitis," Urology, 51(3): 381-7, abstract (Mar. 1998).
CN2	Jimenez, S.A. and Dodge, G.R., "The Effects of Glucosamine Sulfate on Chondrocyte Gene Expression," Euler '96 IX Symposium, Madrid, 7-10 October 1996.
CO2	Katori, M. and Majima, M., "[Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]," Nippon Yakurigaku Zasshi, 109(6): 247-58, abstract (June 1997).
CP2	Katzung, M.D., Ph.D. and Bertram, G., "Other Analgesics, Acetaminophen. In Basic and Clinical Pharmacology, Appleton and Lang, pp. 551-2 (1995).
CO2	Kent, L. et al., "Differential Response of Articular Chondrocyte Populations to Thromboxane B2 and Analogs of Prostaglandin Cyclic Endoperoxidases," Prostaglandins, 19:391-406 (1980).
CR2	Khaled, Z. et al., "Effects of Suramin-related and Other Clinically Therapeutic Polyonans on Protein Kinase C Activity," Clin. Cancer Res. (1): 113-122, abstract (Jan. 1995).
CS2	Kilgore, K., "The Semisynthetic Polysaccharide Pentosan Polysulfate Prevents Complement-Mediated Myocardial Injury in the Rabbit Perfused Heart," J. Pharmacol., Exp. Ther., 265 (3): 987-94 (1998) abstract.
CT2	Kirkpatrick, C.J., "Effects of Prostanoid Precursors and Indomethacin on Chick Embryonic Cartilage Growth in Organ Culture," Exp. Cell. Biol., 51:1922-200 (1993).
CU2	Kirkpatrick, C.J. and Gardner, D.L., "Influence of PGA1 on Cartilage Growth," Experientia, 33 (4): 504 (1976).
CV2	Koopman, W.J., Arthritis and Allied Conditions, A Textbook of Rheumatology, 13(2): 2020-2022.
CW2	Lamaud, M.E., et al., "Biochemical modifications of connective tissue induced by the non-saponifiables of avocado and soy-bean oils administered percutaneously in the 'hairless' rat," Pathol. Biol., 26(5):269-74, abstract.
CX2	Lance, R., Ph.D., et al., "Drug Information Handbook," Lexi-Comp. Inc., American Pharmaceutical Associate, 4: 1-3; 12-15 (1997-98).
CY2	La Villa, G., et al., "Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure," Eur. J. Clin. Pharmacol., 37(1): 1-5, abstract (1989).
CZ2	Lieber, C.S., "Biochemical Factors in Alcoholic Liver Disease," Seminars in Liver Disease, 13(2): 136-153 (1993).
CA3	Lindgren, A. et al., "Paracetamol-induced Cholestatic and Granulomatous Liver Injuries," J. Intern. Med. 241(5): 435-9, abstract (May 1997).
CB3	Lindh, C., et al., "Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopathic pain from a herniated lumbar disc," Scand. J. Rheumatol., 26(6): 468-72.
CC3	Lippiello, L. et al., "Cartilage Stimulatory and Antiproteolytic Activity is Present in Sera of Dogs Treated with a Chondroprotective Agent," Canine Practice, 24(1) (Jan./Feb. 1999).
CD3	Lippiello, L. et al., "Modification of Articular Cartilage Chondrocyte Metabolism by In Vitro Enrichment with Fatty Acids," Trans. Orthop. Res. Soc., 12: 162 (1998).
CE3	Lippiello, L., "Lipid and cell metabolic changes associated with essential fatty acid enrichment of articular chondrocytes," In: Chondrocyte Response to Lipid Loading, Society of Experimental Biology and Medicine (June 1990).
CF3	Lippiello, Louis, "Prostaglandins and articular cartilage metabolism: Does prostaglandin perturbation perpetuate cartilage destruction?," Osteoarthritis Symposium, University of Nebraska Medical Center, Omaha, Nebraska, pp. 87-88.
CG3	Maheu, E. et al., "Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Continuation of 10/192,318
				Filing Date	April 15, 2004
				First Named Inventor	Todd R. Henderson
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	024047.370B-US02
Sheet	6	of	8		

		of osteoarthritis," Arthritis Rheum. 41(1): 81-91 (Jan. 1998).	
CH3	Marshall, J.L. et al., "Phase I Trial of Orally Administered Pentosan Polysulfate in Patients with Advanced Cancer," Clin. Cancer Res., 3(12): 2347-2354, abstract (Dec. 1997).		
CI3	Martel-Pelletier, J. et al., "In vitro effects of diacerein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes," J. Rheumatol., 25(4): 753-62, abstract (April 1998).		
CJ3	Mathews, C., Biochemistry, 2nd ed., Benjamin/Cummings publishing co., Menlo Park, CA, p. 551 (1996).		
CK3	Mathews, C.K. & van Holde, K.E., Biochemistry, 2nd ed., The Benjamin/Cummings Pub. Co., 1996, p. 691.		
CL3	McCord, J.M., "Phagocyte-produced Free Radicals: Roles in Cytotoxicity and Inflammation," Ciba Foundation Symposium 65. Excerpta Medica, Amsterdam-Oxford-New York, pp. 343-360 (1979).		
CM3	McNamara, P. et al., "Hematologic, Hemostatic, and Biochemical Effects in Dogs Receiving an Oral Chondroprotective Agent for Thirty Days," Am. J. Vet. Res. 57(9): 1390-1394, abstract (1996).		
CN3	McNamara, P.S. et al., "Effects of an Oral Chondroprotective Agent (Cosequin) on Cartilage Metabolism and Canine Serum," Veterinary Orthopedic Society, 24th Annual Conference, p. 35 (Mar. 1-8, 1997).		
CO3	McNamara, Paul S., DVM, et al., "Slow-Acting Disease-Modifying Osteoarthritis Agents," Veterinary Clinics of North America: Small Animal Practice, 27(4): 863-867 (Jul. 1997).		
CP3	Mian, M., "Experimental Studies on Diacerein: Effects on the Phagocytosis of Neutrophil Cells from Subcutaneous Carageenan-Induced Exudate," Drugs Exp. Clin. Res., 13(11): 695-8 (1987) abstract.		
CQ3	Miller et al., "Treatment of Dogs with Hip Arthritis with a Fatty Acid Supplement, Canine Practice, 17(6): 6-8 (Nov./Dec. 1992).		
CR3	Mimata, H. et al., "Effects of thiols on prostaglandin synthesis in bovine bladder-epithelium," Urol. Int. 50(3): 129-32, abstract (1993).		
CS3	Mooney, M.A. et al., "Evaluation of the effects of omega-3 fatty acid-containing diets on the inflammatory stage of wound healing in dogs," AM. J. Vet. Res., 59(7):859-63, abstract (July 1998).		
CT3	Moore, A.R. et al., "Effects on diacerein on granuloma induced cartilage breakdown in the mouse," Osteoarthritis Cartilage, 6(1):19-23, abstract (Jan. 1998).		
CU3	Morrison, L.M., MD, et al., "Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans), (1974).		
CV3	Morykwas, M.J. et al., "Arachidonic acid metabolites: effects on inflammation of fetal rabbit excisional wounds," Inflammation, 16(3): 251-8, abstract (June 1992).		
CW3	Nakamura, M., "Archidonic Acid Stimulates Corneal Epithelial Migration," J. Ocul. Pharmacol., summer: 10(2): 453-9 abstract.		
CX3	Newton, G. L. et al., "Low-molecular-weight thiols in streptomyces and their potential role as antioxidants," J. Bacteriol. 175(9): 2734-42, abstract (May 1993).		
CY3	Nguyen, M. et al., "Diacerein in the treatment of osteoarthritis of the hip," Arthritis Rheum., 37(4): 529-36, abstract (Apr. 1994).		
CZ3	Nicolas, P. et al., "Clinical pharmacokinetics of diacerein," Clin. Pharmacokinet, 35(5): 347-59, abstract (Nov. 1998).		
CA4	Oyanagui, Y., "Inflammation and Superoxide Production by Macrophages," Trends in Inflammation Research 1, Agents Actions, Suppl., 7: 174-179 (1980).		
CB4	Paroli, E. et al., "A Pharmacological Approach to Glycosaminoglycans," Drugs under Experimental and Clinical Research 17(1): 9-19 (1991).		
CC4	Paulikova, H. et al., "The effect of heparin and pentosan polysulfate on the thermal stability of yeast alcohol dehydrogenase," Biochem. Mol. Biol. Int., 46(5): 887-94, abstract (Dec. 1998).		

Examiner		Date	
Signature		Considered	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; padding: 2px;">Complete If Known</th> </tr> <tr> <td style="width: 50%; padding: 2px;">Application Number</td> <td style="padding: 2px;">Continuation of 10/192,318</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">April 15, 2004</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Todd R. Henderson</td> </tr> <tr> <td style="padding: 2px;">Art Unit</td> <td style="padding: 2px;">N/A</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Not Yet Assigned</td> </tr> <tr> <td style="padding: 2px;">Attorney Docket Number</td> <td style="padding: 2px;">024047.370B-US02</td> </tr> </table>		Complete If Known		Application Number	Continuation of 10/192,318	Filing Date	April 15, 2004	First Named Inventor	Todd R. Henderson	Art Unit	N/A	Examiner Name	Not Yet Assigned	Attorney Docket Number	024047.370B-US02
Complete If Known																	
Application Number	Continuation of 10/192,318																
Filing Date	April 15, 2004																
First Named Inventor	Todd R. Henderson																
Art Unit	N/A																
Examiner Name	Not Yet Assigned																
Attorney Docket Number	024047.370B-US02																
Sheet	7	of	8														

	CD4	Phan, S.H. et al., "Regulation of MO-derived FGF Release by Arachidonate Metabolites," J. Leukoc. Biol., 42(2): 106-13, abstract (1987).
	CE4	Pietrangelo, A. et al., "Diacerhein blocks iron regulatory protein activation in inflamed human monocytes," Life Sci., 63(14): PL213-9, abstract (1998).
	CF4	Pierno, M. et al., "Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro," Osteoarthritis and Cartilage Journal of the Osteoarthritis Research Society International, 8: 207-212 (2000).
	CG4	Piptone, V.R., "Chondroprotection with Chondroitin Sulfate," Drugs under Research, Drugs Exptl. Clin. Res. XVII(1) 3-7, 1991.
	CH4	Pomarelli, P. et al., "A nonsteroidal anti-inflammatory drug that stimulates prostaglandin release," Farmaco (Sci) 35(10): 836-42, abstract (Oct. 1980).
	CI4	Retzinger, G.S. et al., "Adsorption of fibrinogen to droplets of liquid hydrophobic phases: functionality of the bound protein and biological implications," Arterioscler. Thromb. Vasc. Biol., 18(12): 1948-57, abstract (Dec. 1998).
	CJ4	Robertson, J.T., "Prostaglandin production after experimental discectomy," Spine, 21(15): 1731-6, abstract (Aug. 1996).
	CK4	Roden, Lennart, "Effect of Hexosamines on the Synthesis of Chondroitin Sulphuric Acid in Vitro," Ark. Kemi., (10): 345-352, abstract (1984).
	CL4	Rose, S.R., "Substitutes of Managing Acetaminophen Poisoning," Am. J. Hosp. Pharm. 51(24): 3065-8 (Dec. 15, 1994).
	CM4	Rovati, L.C., "The Practical Clinical Development of a Selective Drug for Osteoarthritis: Glucosamine Sulfate," Euler '96 IX Symposium, Madrid, 7-10 October 1996.
	CN4	Ryan, M., "Potential of Tetracyclines to Modify Cartilage Breakdown in Osteoarthritis," Curr. Opin. Rheumatol., 8 (3): 238-47 (1996) abstract.
	CO4	Scharrer, E. et al., "Stimulation of mucosal uptake of selenium from selenite by some thiols at various sites of rat intestine," Biol. Trace Elem. Res. 33: 109-20, abstract (Apr-Jun. 1992).
	CP4	Shires, T.K. et al., "Egothioneine distribution in bovine and porcine ocular tissues," Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol., 117(2): 117-20, abstract (May 1997).
	CQ4	Smith, G.N., Jr., et al., "Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage," J. Rheumatol., 25(3): 532-5, abstract (Mar. 1998).
	CR4	Smith, R.C. et al., "Inhibition by thiols of copper(II)-induced oxidation of oxyhemoglobin," Chem. Biol. Interact., 82(2): 209-17, abstract (Apr. 15, 1992).
	CS4	Spencer, C., "Diacerhein," Drugs, 53(1): 98-106 (1997).
	CT4	Srinivasan, B.D., "Corneal reepithelialization and anti-inflammatory agents," Trans. AM Ophthalmol. Soc., 80:758-822, abstract (1982).
	CU4	Stramentinoli, G., Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics, Am. J. Med., 83(5A): 35-42 (1987).
	CV4	Thiers, M.H., "Unsaponifiable constituents of avocado and soya oils. Treatment of certain forms of arthralgia," J. Med. Lyon 53(222): 195-8 (English summary, p. 198) (Feb. 1972).
	CW4	Todhunter, R.J. et al., "Effects of Exercise and Polysulfated Glycosaminoglycan on the Development of Osteoarthritis in Equine Carpal Joints with Osteochondral Defects," Vet. Surgery, 22(5): 330-342, abstract.
	CX4	Trentham, D.E. et al., "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis," Science, 261: 1727-30 (September 24, 1993).
	CY4	Trentham, David E., "Evidence That Type II Collagen Feeding Can Induce a Durable Therapeutic Response in Some Patients with Rheumatoid Arthritis," Ann. N.Y. of Academy Sciences, pp. 778-306-14 (1996).
	CZ4	Trevoux, R., "Unsaponifiable fractions of the avocado and soybean in gynecology," J. Gynecol. Obstet. Biol. Reprod. 6(1): 99-105 (article in French) (English abstract) (Jan. 1977).
	CA5	Van der Kraan, P.M. et al., "The Effect of Chronic Paracetamol Administration to Rats on the

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				<b>Application Number</b>	Continuation of 10/192,318
				<b>Filing Date</b>	April 15, 2004
				<b>First Named Inventor</b>	Todd R. Henderson
				<b>Art Unit</b>	N/A
				<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	8	of	8	<b>Attorney Docket Number</b>	024047.370B-US02

		Glycosaminoglycan Content of Patellar Cartilage," Agents Actions, 29(3-4): 218-223, abstract (March 1990).	
	CB5	Vann Der Kraan, P.M. et al., Inhibition of Glycosaminoglycan Synthesis in Anatomically Intact Rat Patellar Cartilage by Paracetamol-Induced Serum Sulfate Depletion," Biochem. Pharmacol. 37(19): 3683-3690, abstract.	
	CC5	Villani, P. and Bouvenot, G., "Assessment of the Placebo Effect of symptomatic Slow-Acting Anti-Arthritics," Med. Press, published on PubMed Central-indexed for MEDLINE (Feb. 7, 1998).	
	CD5	Wallace, J.L. et al., "Comparison of the damage-promoting effects of leukotrienes derived from eicosapentaenoic acid and arachidonic acid on the rat stomach," J. Exp. Med., 171(5): 1827-32, abstract (May 1990).	
	CE5	Yu, L.P., Jr., et al., "Effects of oral doxycycline administration on histomorphometry and dynamics of subchondral bone in a canine model of osteoarthritis," J. Rheumatol. 23 (1): 137-42, abstract (Jan. 1996).	
	CF5	Yunmbam, M.K., "Inhibition of breast cancer in nude mouse model by anti-angiogenesis," Oncol. Rep., 5(6): 1431-7, abstract (Nov-Dec. 1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

<b>Examiner Signature</b>	/Shengjun Wang/	<b>Date Considered</b>	02/11/2008
---------------------------	-----------------	------------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./